Skip to content
Evigrade
CriticalSNRI×Selective irreversible MAO-B inhibitor

Updated · Methodology

Mechanism

Selegiline irreversibly inhibits the enzyme monoamine oxidase (MAO) type B. At the recommended dose of 5–10 mg a day it acts selectively on MAO-B, and above 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After a single 10 mg dose of selegiline, platelet MAO-B activity returns to normal in about 2 weeks, as the body makes new enzyme (selegiline SmPC, AEMPS). MAO takes part in the breakdown of serotonin and catecholamines (selegiline label, US Food and Drug Administration, FDA). Duloxetine inhibits the reuptake of serotonin and noradrenaline but does not inhibit MAO itself (duloxetine SmPC, European Medicines Agency, EMA; duloxetine FDA label). The Spanish selegiline SmPC contraindicates selegiline with serotonin and noradrenaline reuptake inhibitors because of the risk of serotonin syndrome (selegiline SmPC, AEMPS). Serotonin syndrome has been reported when antidepressants, including this class, were combined with selegiline. Some cases were fatal, and the mechanism of these reactions is not fully understood (selegiline FDA label).

Symptoms

Selegiline combined with serotonin and noradrenaline reuptake inhibitors, the class duloxetine belongs to, may cause confusion, hypomania, hallucinations and manic episodes, agitation, myoclonus, overactive reflexes, poor coordination, shivering, tremor, seizures, ataxia, sweating, diarrhoea, fever and high blood pressure, all of which can be part of serotonin syndrome (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). During duloxetine treatment, serotonin syndrome may present with mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, fever), neuromuscular abnormalities (overactive reflexes, poor coordination), nausea, vomiting and diarrhoea (duloxetine SmPC, European Medicines Agency, EMA). In its most severe form it can resemble neuroleptic malignant syndrome, with fever, muscle rigidity, raised serum creatine kinase, autonomic instability with rapid swings in vital signs and mental status changes (duloxetine SmPC, EMA).

Management

The combination is contraindicated. The Spanish selegiline summary of product characteristics (SmPC) contraindicates selegiline with serotonin and noradrenaline reuptake inhibitors as a class and lists the combination as contraindicated. According to its own SmPC, duloxetine belongs to this class (selegiline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; duloxetine SmPC, European Medicines Agency, EMA). The US label for the selegiline patch for depression names duloxetine among the contraindicated drugs, and the US duloxetine label contraindicates duloxetine with monoamine oxidase (MAO) inhibitors (selegiline and duloxetine labels, US Food and Drug Administration, FDA). The European duloxetine SmPC is less strict: it contraindicates only irreversible non-selective MAO inhibitors, and at the recommended dose selegiline inhibits MAO-B selectively (duloxetine SmPC, EMA; selegiline SmPC, AEMPS). The strictest document takes precedence. Start duloxetine no earlier than 14 days after stopping selegiline (selegiline FDA label). Allow at least 5 days between the last dose of duloxetine and the first dose of an MAO inhibitor (duloxetine SmPC, EMA, and FDA label). If a patient is nevertheless taking both drugs and signs of serotonin syndrome appear, stop duloxetine and selegiline at once and start supportive symptomatic treatment (duloxetine FDA label; selegiline patch FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Duloxetine

Other interactions with Selegiline